Related Experiment Video
Updated: Nov 16, 2025
05:45
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
9.9K
Cannabinoids in glioblastoma multiforme-hype or hope?
Gary J Doherty1,2, Bruno H R de Paula3,4,5
1Department of Oncology, Cambridge University Hospitals NHS Foundation, Trust, Cambridge Biomedical Campus, Cambridge, UK. gd231@cam.ac.uk.
British Journal of Cancer
|February 24, 2021
Summary
Cannabis derivatives show potential against glioblastoma multiforme (GBM), but clinical data is limited. A Phase 1b trial explored nabiximols with temozolomide in recurrent GBM patients.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Increasing use of cannabis derivatives in cancer care, particularly for glioblastoma multiforme (GBM).
- Preclinical studies suggest cannabinoids possess anti-cancer properties relevant to GBM.
- Lack of robust clinical and safety data for cannabinoid use in GBM patients.
Discussion:
- Focus on a Phase 1b trial evaluating nabiximols oromucosal spray combined with dose-intense temozolomide.
- Contextualizes trial findings within existing research on cannabinoids and GBM.
- Addresses the clinical application and safety profile of this combination therapy.
Key Insights:
- Highlights the need for more clinical evidence on cannabis-based therapies in oncology.
- Emphasizes the potential therapeutic role of cannabinoids in aggressive brain tumors like GBM.
- Underscores the importance of evaluating drug combinations for recurrent GBM treatment.
Outlook:
- Further clinical trials are necessary to establish efficacy and safety of nabiximols in GBM.
- Exploration of cannabinoid mechanisms in brain tumor models warrants continued investigation.
- Potential for novel therapeutic strategies combining cannabinoids with standard chemotherapy.
